ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NRXP / earnings
ORGO (34) PMVP (42) VTVT (24) NTHI (31) ⌘ Pro Terminal →

NRX Pharmaceuticals Inc. (NRXP) Next Earnings Date & Expected ±12.5% Move

$2.17 -4.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.15

NRX Pharmaceuticals Inc. (NRXP) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $98.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NRXP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NRXP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, NRX Pharmaceuticals Inc. (NASDAQ: NRXP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $2.17 (-4.40% 1D, market cap $98.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NRXP ranks #926 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NRXP compare to ORGO and PMVP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NRXP carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of 58.8%, and ROIC of -35.0%. By comparison, ORGO (Organogenesis Holdings Inc. (Class A)) holds a E grade (34/100 RQD, P/E N/A, ROIC 17.1%, cap $98.8M) and PMVP (PMV Pharmaceuticals Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $98.9M). Among the 5-stock peer group, NRXP leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NRXP?
▼

Per NRXP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001719406), NRX Pharmaceuticals Inc. generated $1.2M in revenue (-97.6% YoY), -$28.6M in net income, and -$14.1M in free cash flow against $13.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.15 (-0.98%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510025
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (6)Whales (4)SEC (8)Macro (4)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14.7% Base Target
$5 Bull$2 Base$1 Bear
📬 FREE NRXP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NRXP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (25/100 Composite)
🔍 WHY NRXP SCORES 25/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 58.8% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
33
Grade E$2.70-3% Next Q
Q2 (-2Q)
30
Grade E$2.62+2.7% Next Q
Q3 (-1Q)
28
Grade E$2.69-19.3% Next Q
Current
25
Grade E$2.17-10.7% Hist 90D α
Trajectory: E (33) → E (25)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NRXP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NRXP currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.01) and Max Pain ($2.28) forces dealer call-delta covering toward $5.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NRXP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NRXP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 25%NO 75%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.27 Expected Swing
$1.90 (-12.5%)Spot $2.17$2.44 (+12.5%)
MODEL EARNINGS SETUP GAUGE

NRXP Quantitative Pre-Earnings Setup: 25/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (25/100)Model Risk Weight (75/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$1.2M-$28.6M-$14.1M58.8%
FY 20242024-12-31$51.8M-$25.1M-$10.6M58.8%
FY 20232023-12-31$77.9M-$30.1M-$21.7M58.8%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NRXP)

  • ✓Walkthrough of NRXP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NRXP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.67%🛡️ HOLDING TREND SUPPORT
2026-11-03O $2.66H $2.66L $2.17C $2.17VOL 15.64M
RES: $2.80SUP: $2.09SMA50: $3.01SMA200: $2.97
$5.26$4.40$3.55$2.70$1.85RES $2.80SUP $2.09$2.172026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NRXP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NRXP Butterfly Map → + Track NRXP →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -97.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NRXP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NRXP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NRXP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NRXP)

Health Care Rank #926 of 1015 ⚔️ ORGO vs NRXP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NRXP vs. ORGO, PMVP, VTVT, NTHI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, NRX Pharmaceuticals Inc. (NRXP) ranks #926 by composite RQD confidence (25/100, grade E) and #656 by equity capitalization ($98.3M). Within this direct 5-issuer industry benchmark cohort, NRXP leads on earnings valuation at N/A trailing P/E, while ORGO leads on capital efficiency and profitability with 17.1% ROIC and — gross margin. PMVP currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with NRXP at 25/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NRXP ACTIVE
NRX Pharmaceuticals Inc.
E 25/100 — 58.8% -35.0% -4.40% $98.3M Benchmark Subject
ORGO
Organogenesis Holdings Inc. (Class A)
E 34/100 — — 17.1% -1.64% $98.8M /orgo-vs-nrxp →
PMVP
PMV Pharmaceuticals Inc.
D- 42/100 — — -35.0% +4.58% $98.9M /pmvp-vs-nrxp →
VTVT
vTv Therapeutics Inc. (Class A)
E 24/100 — — -35.0% -4.05% $99.5M /vtvt-vs-nrxp →
NTHI
NeOnc Technologies Holdings Inc.
E 31/100 — — -35.0% -5.83% $97.0M /nthi-vs-nrxp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001719406 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NRX Pharmaceuticals Inc. (NRXP) reported GAAP revenue of $1.2M (-97.6% vs. FY2024 revenue of $51.8M , and -98.4% cumulative change since FY2023) , GAAP net income of -$28.6M, operating cash flow of -$14.1M, and free cash flow of -$14.1M (-32.7% YoY). On the balance sheet, NRXP closed FY2025 with $13.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.2M -$28.6M -$14.1M -$14.1M $13.0M —
FY2024 (FY) 2024-12-31 $51.8M -$25.1M -$10.6M -$10.6M $3.7M —
FY2023 (FY) 2023-12-31 $77.9M -$30.1M -$21.7M -$21.7M — —

3. NRXP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NRXP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, NRX Pharmaceuticals Inc. (NASDAQ: NRXP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $2.17 (-4.40% 1D, market cap $98.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NRXP ranks #926 in composite RQD confidence.

How does NRXP compare to ORGO and PMVP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NRXP carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of 58.8%, and ROIC of -35.0%. By comparison, ORGO (Organogenesis Holdings Inc. (Class A)) holds a E grade (34/100 RQD, P/E N/A, ROIC 17.1%, cap $98.8M) and PMVP (PMV Pharmaceuticals Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $98.9M). Among the 5-stock peer group, NRXP leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NRXP?

Per NRXP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001719406), NRX Pharmaceuticals Inc. generated $1.2M in revenue (-97.6% YoY), -$28.6M in net income, and -$14.1M in free cash flow against $13.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NRXP trading relative to its 50-day, 200-day, and 52-week technical levels?

NRXP last traded at $2.17 (-4.40% on volume of 2,510,371 shares), positioning the stock -27.91% below its 50-day simple moving average ($3.01) and -26.94% below its 200-day simple moving average ($2.97). Across its 52-week range of $1.62 to $5.05, NRXP sits at the 16.0% percentile with a 14-day RSI of 32.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.90 to $2.44).

Direct Sub-Reports: NRXP RQD Cockpit NRXP 12M Forecast NRXP Earnings & Move NRXP Dividends & DRIP NRXP Insiders & 13F NRXP Whale Options NRXP Profit Sankey NRXP News & Why
ROARABLE RATING BRIEF • RQD 25/100 (E) ✓ SEC XBRL & RQD VERIFIED

NRXP — NRX Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

NRX Pharmaceuticals Inc. (NRXP) earns a live Roarable RQD composite score of 25/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.17 (-4.40% 1D, market capitalization $98.3M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 58.8%, operating margin of -60.0%, and free cash flow yield of -12.25%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (4/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

NRX Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $0.1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), NRX Pharmaceuticals Inc. (NRXP) reported $1.2M in annual revenue (up from $51.8M in FY2024, -97.6% YoY) and -$28.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($77.9M revenue, -$30.1M net income) through FY2025, NRXP scaled operating cash flow to -$14.1M and free cash flow to -$14.1M, backed by $13.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 25/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -12.25% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $1.62 – $5.05 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The only sector context available is the Health Care classification and the beta of 1.0, which suggests the stock moves in line with the broader market rather than with a distinct sector factor.

  • Key Question #1: Can NRXP sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.2M and free cash flow of -$14.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NRXP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NRXP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NRX Pharmaceuticals Inc. (NRXP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NRXP Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NRXP Bull vs. Bear Conversation Board — What's Your Call at $2.17?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NRXP 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NRXP:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $2.72 (+19.8%)
📌 Pinned Debate

Cash rose to $7.8M in FY 2025 and the stock posted a 26% after-hours jump per the TradingView headline, signaling a potential near-term

Long NRXP at $2.27 targeting $2.72. Cash rose to $7.8M in FY 2025 and the stock posted a 26% after-hours jump per the TradingView headline, signaling a potential near-term catalyst.. Institutional whale score is 4/20 and the risk/reward vs. the $1.62 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@TapeReader_Pro Agree on the RQD 25/100 quality, though with 1.0 beta I'm scaling in with half-size at $2.27 and keeping dry powder in case we test $2.11.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $1.91 (-15.9%)
Spot @ $2.27

FY 2025 FCF of -$14.1M against $7.8M cash, with ROIC at -35% and an insider conviction pillar of only 3/20, points to cash burn and lim

Here is the bear case nobody on the bull side wants to address on NRXP: FY 2025 FCF of -$14.1M against $7.8M cash, with ROIC at -35% and an insider conviction pillar of only 3/20, points to cash burn and limited insider confidence.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE